Exome Asset Management LLC
Exome Asset Management LLC reported 55 holdings worth US$153M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Exome Asset Management LLC reported 55 holdings worth US$153M as of Sep 30, 2026. Largest: Guardant Health, Inc., TG Therapeutics, Inc. and Abivax SA. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 55
- Value as reported
- US$153M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Guardant Health, Inc. | 67,500 | US$12M | 7.9% |
| TG Therapeutics, Inc. | 188K | US$10.5M | 6.8% |
| Abivax SA | 90,919 | US$9M | 5.9% |
| Praxis Precision Medicines, Inc. | 29,681 | US$8.64M | 5.6% |
| Cogent Biosciences, Inc. | 211K | US$6.74M | 4.4% |
| Eli Lilly and Company | 5,492 | US$6.35M | 4.2% |
| Natera, Inc. | 13,800 | US$5.7M | 3.7% |
| Vera Therapeutics, Inc. | 160K | US$5.15M | 3.4% |
| Viking Therapeutics, Inc. | 147K | US$4.81M | 3.1% |
| Ionis Pharmaceuticals, Inc. | 107K | US$4.78M | 3.1% |
| Enliven Therapeutics, Inc. | 100K | US$4.59M | 3.0% |
| Caris Life Sciences, Inc. | 146K | US$4.47M | 2.9% |
| Nektar Therapeutics | 73,708 | US$4.46M | 2.9% |
| Cytokinetics, Incorporated | 60,056 | US$3.96M | 2.6% |
| Verastem, Inc. | 429K | US$3.45M | 2.3% |
| Maze Therapeutics, Inc. | 115K | US$3.12M | 2.0% |
| Rhythm Pharmaceuticals, Inc. | 32,209 | US$3.07M | 2.0% |
| 10x Genomics, Inc. | 30,074 | US$2.72M | 1.8% |
| United Therapeutics Corporation | 4,109 | US$2.23M | 1.5% |
| Boston Scientific Corporation | 48,347 | US$2.11M | 1.4% |
| Arrowhead Pharmaceuticals, Inc. | 32,214 | US$2.11M | 1.4% |
| UnitedHealth Group Incorporated | 5,697 | US$2.09M | 1.4% |
| Ocular Therapeutix, Inc. | 272K | US$2.09M | 1.4% |
| Alumis Inc. | 282K | US$2.09M | 1.4% |
| Penumbra, Inc. | 6,300 | US$2.01M | 1.3% |
| Intuitive Surgical, Inc. | 4,908 | US$2M | 1.3% |
| COMPASS Pathways Plc | 153K | US$1.9M | 1.2% |
| Celldex Therapeutics, Inc. | 56,269 | US$1.82M | 1.2% |
| Merck & Company, Inc. | 12,358 | US$1.8M | 1.2% |
| Liquidia Corporation | 59,155 | US$1.79M | 1.2% |
| Glaukos Corporation | 10,862 | US$1.78M | 1.2% |
| Monte Rosa Therapeutics, Inc. | 137K | US$1.63M | 1.1% |
| BridgeBio Pharma, Inc. | 21,209 | US$1.4M | 0.91% |
| ClearPoint Neuro Inc. | 110K | US$1.35M | 0.88% |
| Corbus Pharmaceuticals Holdings, Inc. | 191K | US$1.3M | 0.85% |
| CytomX Therapeutics, Inc. | 460K | US$1.25M | 0.82% |
| Palvella Therapeutics, Inc. | 7,809 | US$1.08M | 0.70% |
| Rapport Therapeutics, Inc. | 29,381 | US$987K | 0.65% |
| BillionToOne, Inc. | 8,983 | US$956K | 0.62% |
| Zenas BioPharma, Inc. | 34,341 | US$926K | 0.61% |
| Replimune Group, Inc. | 68,488 | US$907K | 0.59% |
| Equillium, Inc. | 553K | US$899K | 0.59% |
| Establishment Labs Holdings Inc. | 13,100 | US$841K | 0.55% |
| Climb Bio, Inc. | 71,215 | US$817K | 0.53% |
| NovaBridge Biosciences | 577K | US$788K | 0.51% |
| Bright Minds Biosciences Inc. | 14,715 | US$733K | 0.48% |
| Compass Therapeutics, Inc. | 511K | US$532K | 0.35% |
| Q32 Bio Inc. | 62,589 | US$518K | 0.34% |
| Capricor Therapeutics, Inc. | 51,531 | US$488K | 0.32% |
| Arbutus Biopharma Corporation | 50,166 | US$240K | 0.16% |
| Adagene, Inc. | 52,543 | US$168K | 0.11% |
| Geron Corporation | 0 | US$0 | 0.00% |
| Insmed Incorporated | 0 | US$0 | 0.00% |
| Relay Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Crescent Biopharma, Inc. | 0 | US$0 | 0.00% |
| Agios Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related